Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1

Conditions

Multiple Myeloma 55Neoplasms, Plasma Cell 22Central Nervous System Neoplasms 10Prostatic Neoplasms 9Glioblastoma 9Recurrence 8Melanoma 8Brain Neoplasms 8Neoplasms 7Gliosarcoma 7Carcinoma, Non-Small-Cell Lung 7Sarcoma 6Leukemia 6Carcinoma, Hepatocellular 6Waldenstrom Macroglobulinemia 5Myeloproliferative Disorders 5Lung Neoplasms 5Leukemia, Lymphocytic, Chronic, B-Cell 5Glioma 5Colorectal Neoplasms 5Myelodysplastic-Myeloproliferative Diseases 4Myelodysplastic Syndromes 4Lymphoma 4Liver Neoplasms 4Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 4Kidney Neoplasms 4Carcinoma, Renal Cell 4Lymphoma, Mantle-Cell 3Lymphoma, B-Cell, Marginal Zone 3Leukemia, Myelomonocytic, Chronic 3

Interventions

lutetium Lu 177 dotatate 15Everolimus 11Nivolumab 10pembrolizumab 9Temozolomide 9Capecitabine 7cabozantinib 6Sunitinib 6lenvatinib 5lanreotide 4gallium Ga 68 dotatate 4Ipilimumab 4Etoposide 4Carboplatin 4177Lu-octreotide, DOTA(0)-Tyr(3)- 4telotristat ethyl 3pazopanib 3avelumab 3Octreotide 3Magnetic Resonance Spectroscopy 3Injections 3Cyclophosphamide 3Cisplatin 3Bevacizumab 3surufatinib 2sintilimab 2fosbretabulin 2fludarabine 2Specimen Handling 2Sorafenib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Neuroendocrine Tumors × Thalidomide × Clear all
NCT00165230 2009-04-28

Thalidomide in Combination With Temodar in Patients With Neuroendocrine Tumors

Dana-Farber Cancer Institute

Phase 2 Completed
32 enrolled
EndocrineNET

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡